Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 4:11:1155853.
doi: 10.3389/fped.2023.1155853. eCollection 2023.

Management of children with hemophilia A on emicizumab who need surgery

Mark Belletrutti  1 , Mihir Bhatt  2 , Nasrin Samji  2
Affiliations
Review

Management of children with hemophilia A on emicizumab who need surgery

Mark Belletrutti et al. Front Pediatr. .

Abstract

The introduction of emicizumab into the treatment regime of persons with hemophilia A has dramatically reduced frequency of bleeding in patients with and without inhibitors. However, in children with Hemophilia A (CwHA) who require surgical or other invasive procedures, additional treatment with factor replacement or other hemostatic agents may still be needed to prevent intraoperative or postoperative bleeding. This review will look at the reported outcomes in CwHA on emicizumab who have had surgery and propose recommendations for the best perioperative management of major and minor procedures.

Keywords: bleeding; emicizumab; hemophilia A; pediatric; surgery.

PubMed Disclaimer

Conflict of interest statement

MBe: Advisory Board attendee with Roche Canada, Sanofi Canada, Bayer Canada, Octapharma Canada; invited speaker for Roche Canada, Octapharma Canada. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia. (2020) 26(Suppl 6):1–158. 10.1111/hae.14046 - DOI - PubMed
    1. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. (2007) 357(6):535–44. 10.1056/NEJMoa067659 - DOI - PubMed
    1. Fischer K, Collins PW, Ozelo MC, Srivastava A, Young G, Blanchette VS. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. J Thromb Haemost. (2016) 14(5):1105–9. 10.1111/jth.13298 - DOI - PubMed
    1. Van Dijk K, Van Der Bom JG, Bax KNMA, Van Der Zee DC, Van Den Berg MH. Use of implantable venous access devices in children with severe hemophilia: benefits and burden. Haematologica. (2004) 89(2):189–94. 10.3324/%x - DOI - PubMed
    1. Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. (2013) 121:4046–55. 10.1182/blood-2012-09-457036 - DOI - PubMed

LinkOut - more resources